Delphia (USA)’s TG Therapeutics TGTX Stock Holding History

Delphia (USA)’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,867	Closed	-$55K	–	418
2022 Q2	$55K	Buy	+12,867	New	+$80.3K	0.04%	369

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Delphia (USA)'s TGTX Position: Q3 2022 in Review

Delphia (USA) sold out of TG Therapeutics (TGTX) in Q3 2022, closing a stake of 12,867 shares — an estimated $55K sold.

Delphia (USA) first reported a position in TGTX in Q2 2022 and held it in 1 quarter. The position peaked at $55K in Q2 2022. 183 funds tracked by Wall St. Rank hold TGTX as of Q3 2022.

Delphia (USA) reported no remaining TG Therapeutics position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 12,867 TG Therapeutics shares in Q3 2022, an estimated $55K.
Delphia (USA) first reported a position in TG Therapeutics in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s TG Therapeutics position peaked at $55K in Q2 2022.
183 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.